Free Trial

Hepion Pharmaceuticals (HEPA) Insider Trading & Ownership

Hepion Pharmaceuticals logo
$0.48 -0.13 (-21.31%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$0.46 -0.02 (-3.12%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hepion Pharmaceuticals (NASDAQ:HEPA) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
4.70%
Number Of
Insiders Buying
(Last 3 Years)
2
Amount Of
Insider Buying
(Last 3 Years)
$49,790.00
Number Of
Insiders Selling
(Last 3 Years)
0
Get HEPA Insider Trade Alerts

Want to know when executives and insiders are buying or selling Hepion Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

HEPA Insider Buying and Selling by Quarter

Remove Ads

Hepion Pharmaceuticals Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/27/2023Peter WijngaardDirectorBuy50$152.50$7,625.00  
11/24/2023Peter WijngaardDirectorBuy50$154.50$7,725.00  
9/19/2023Peter WijngaardDirectorBuy20$282.00$5,640.00  
9/18/2023Robert T FosterCEOBuy32$280.00$8,960.00  
9/15/2023Peter WijngaardDirectorBuy40$280.00$11,200.00  
9/15/2023Robert T FosterCEOBuy32$270.00$8,640.00  
(Data available from 1/1/2013 forward)

HEPA Insider Trading Activity - Frequently Asked Questions

The list of insiders at Hepion Pharmaceuticals includes Peter Wijngaard, and Robert T Foster. Learn more on insiders at HEPA.

4.70% of Hepion Pharmaceuticals stock is owned by insiders. Learn more on HEPA's insider holdings.

The following insiders have purchased HEPA shares in the last 24 months: Peter Wijngaard ($32,190.00), and Robert T Foster ($17,600.00).

Insiders have purchased a total of 224 HEPA shares in the last 24 months for a total of $49,790.00 bought.

Hepion Pharmaceuticals Key Executives

  • Mr. John T. Cavan (Age 66)
    Interim CEO & CFO
    Compensation: $495.33k
  • Sharen Pyatetskaya
    Director of Investor Relations
  • Dr. John Z. Sullivan-Bolyai (Age 76)
    Part-Time Consultant
  • Dr. Stephen A. Harrison FACP
    M.D., Scientific Advisory Board Chair & Consultant Medical Director


This page (NASDAQ:HEPA) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners